Literature DB >> 15482675

[In vitro antibacterial activity of cefdinir against isolates of respiratory tract pathogens in children].

Quan Lu1, Hong Zhang, Da-tian Che, Wan-hua Li.   

Abstract

OBJECTIVE: To study the in vitro antibacterial activity of cefdinir against clinical isolates of respiratory tract pathogens in Children.
METHODS: MIC values of cefdinir against 380 strains were determined with E-test method and compared with those of cefaclor.
RESULTS: All penicillin-susceptible Streptococcus pneumoniae (PSSP) strains were also susceptible to cefdinir and cefaclor. Both cefdinir and cefaclor were not active against penicillin-resistant SP (PRSP). Against penicillin-intermediate SP (PISP) the susceptibility rates of cefdinir and cefaclor were 70.1% and 57.4%, respectively. The activity of cefdinir and cefaclor against beta-lactamases negative Hemophilus influenzae (HI) was excellent, but the susceptibility rates of cefdinir and cefaclor against beta-lactamases positive HI were 85.0% and 70.0%, respectively with MIC(90) of 1.5 mg/L vs. 256.0 mg/L. Cefdinir presented higher activities and lower MIC values than cefaclor against Moraxella catarrhalis (MC), Group A streptococcus (GAS), methicillin susceptible staphylococcus aureus (MSSA), and extended spectrum beta-lactamases (ESBLs) negative Escherichia coli (E. coli) or Klebsiella pneumoniae (K. pn). Both cefdinir and cefaclor were not susceptible to ESBLs positive E. coli and K. pn.
CONCLUSIONS: Cefdinir exhibits excellent activity against PSSP, PISP, HI, as well as MC, GAS, MSSA and ESBLs negative E. coli or K. pn.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15482675

Source DB:  PubMed          Journal:  Zhonghua Er Ke Za Zhi        ISSN: 0578-1310


  1 in total

1.  Design and development of cefdinir niosomes for oral delivery.

Authors:  Saurabh Bansal; Geeta Aggarwal; Pankaj Chandel; S L Harikumar
Journal:  J Pharm Bioallied Sci       Date:  2013-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.